|
Synonyms: OPN-305 | OPN305 | VK5A/H4
Compound class:
Antibody
Comment: Tomaralimab (OPN305) is a first-in-class humanised monoclonal antibody against Toll-like receptor 2 (TLR2) being developed by Opsona Therapeutics. It is being investigated for potential clinical use in certain hematological and immunological conditions. OPN305 and its possible uses are claimed in patent WO2011003925 [4]. The effect of TLR2 antagonism on myocardial ischemia/reperfusion injury in a large animal model (pigs) is reported in [1].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| OPN305 is in clinical trial: Phase 1/2 as a second-line therapy for lower risk myelodysplastic syndrome (MDS; NCT02363491) and Phase 2 for potential to prevent delayed renal graft function (NCT01794663), which is a complication encountered in renal transplantation. The EMA granted OPN305 orphan designation for the tretament of MDS in Aug 2016. |
| Mechanism Of Action and Pharmacodynamic Effects |
| It is hypothesised that TLR2 on hematopoietic cells mediates ischemia/reperfusion injury. TLR2 is believed to initiate a damaging inflammatory response (including rapid increase in cytokines, chemokines and leukocyte influx) in reperfused tissue. Experiments in TLR2-null mice and TLR2 activation studies validate this hypoyhesis [3,6]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT01794663 | Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function | Phase 2 Interventional | Opsona Therapeutics Ltd. | ||
| NCT02363491 | A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome | Phase 1/Phase 2 Interventional | Opsona Therapeutics Ltd. | ||
